Literature Analysis: Optimizing Prostate Cancer Detection and Diagnosis with PSA Recombinant Rabbit Monoclonal Antibodies Literature Information
Literature Analysis: Optimizing Prostate Cancer Detection and Diagnosis with PSA Recombinant Rabbit Monoclonal Antibodies
Literature Information
Title: How to optimize the detection and diagnosis of prostate cancer with PSA recombinant rabbit monoclonal antibody
Core Theme: Enhancement of prostate cancer early screening, PSA biomarker performance improvement, and high‑performance antibody applications in in vitro diagnostics
Research Background
Prostate cancer represents one of the most prevalent malignant tumors threatening male health worldwide, with its incidence increasing substantially with age. The disease progresses silently with no overt early symptoms, leading many patients to present at advanced stages and miss the optimal therapeutic window.
Current clinical screening relies mainly on digital rectal examination and prostate‑specific antigen (PSA) testing. PSA assay is the most widely adopted non‑invasive serological method due to its accessibility and moderate sensitivity. However, total PSA suffers from limited specificity: benign prostatic hyperplasia, inflammation, and certain urological procedures frequently cause false‑positive elevations, especially within the diagnostically challenging 4–10 ng/mL “gray zone”. This unmet clinical need strongly drives the development of higher‑specificity and higher‑sensitivity detection tools, where high‑quality anti‑PSA antibodies serve as indispensable core reagents.
Research Approach
This study systematically dissects the clinical challenges in early prostate cancer diagnosis, clarifies the biological function of PSA and the pathological basis of serum concentration changes, explores the value of PSA isoform (fPSA/tPSA) analysis in improving diagnostic specificity, evaluates the technical superiority of recombinant rabbit monoclonal antibodies over traditional antibody reagents, identifies pre‑analytical factors that interfere with PSA measurements, and validates the translational potential of high‑performance PSA recombinant antibodies across diagnostic and research applications.
Research Outcomes
- Biological and Pathological Basis of PSA
PSA is a serine protease produced by prostate epithelial cells, primarily responsible for semen liquefaction. Under physiological conditions, the blood‑epithelial barrier restricts PSA leakage, maintaining serum levels below 4.0 ng/mL. Malignant transformation disrupts this barrier and triggers excessive PSA secretion, leading to elevated serum concentrations. Although PSA levels correlate with tumor burden, total PSA cannot reliably differentiate benign prostatic hyperplasia from early‑stage prostate cancer in the 4–10 ng/mL gray zone.
- PSA Isoform Analysis Improves Diagnostic Specificity
Circulating PSA exists mainly as free PSA (fPSA) and complexed PSA. Prostate cancer patients typically show a lower fPSA/tPSA ratio. A ratio below a clinical threshold (e.g., 0.19) significantly increases the probability of malignancy, effectively reducing unnecessary biopsies in the gray zone. Accurate quantification of fPSA and tPSA requires antibodies with high specificity, sensitivity, and epitope selectivity.
- Superiority of Recombinant Rabbit Monoclonal Antibodies
Compared with polyclonal or mouse monoclonal antibodies, recombinant rabbit monoclonal antibodies offer multiple advantages:
- Standardized large‑scale production enabling exceptional batch‑to‑batch consistency
- Higher antigen affinity supporting enhanced detection sensitivity
- Genetically tunable epitope recognition for specific discrimination between fPSA and complexed PSA
- Ready conjugation with enzymes, fluorophores, or biotin for compatibility with multiple immunoassay platforms
- Pre‑Analytical Interference Factors
Benign prostatic diseases, urological interventions, ejaculation, and 5α‑reductase inhibitors can alter serum PSA levels and confound diagnostic interpretation. Clinicians must review patient history, medications, and recent procedures to avoid misdiagnosis.
Product Empowerment
ANT BIO PTE. LTD. delivers high‑performance PSA recombinant rabbit monoclonal antibody as a core reagent to revolutionize prostate cancer detection systems.
Developed using advanced recombinant antibody technology, the Starter‑branded PSA Recombinant Rabbit Monoclonal Antibody (SDT‑195‑14, Cat. No. S0B2133) enables highly specific and sensitive recognition of PSA epitopes, minimizes cross‑reactivity with kallikrein family proteins, and supports robust, reproducible quantification of total PSA and free PSA.
Key Contributions to Research and Diagnostics:
- Serves as capture or detection antibody in high‑sensitivity CLIA, ELISA, and immunochromatographic assays
- Enables specific IHC staining for prostate cancer diagnosis, grading, and differential diagnosis
- Supports high‑sensitivity liquid biopsy, CTC enrichment, and MRD monitoring
- Provides reliable tools for investigating PSA biology, cancer mechanisms, and targeted therapy development
Core Product Advantages
表格
|
Core Product Advantages |
|
Exceptional Specificity and High Affinity: Engineered via advanced recombinant technology to precisely target PSA epitopes; superior specificity and affinity over conventional mouse monoclonal or polyclonal antibodies, minimizing cross‑reactivity and ensuring accurate results. |
|
Excellent Batch‑to‑Batch Consistency and Stability: Recombinant production guarantees uniform sensitivity, specificity, and potency across batches; outstanding stability supports large‑scale IVD manufacturing, long‑term studies, and multi‑center trials. |
|
Broad Platform Compatibility: Validated for IHC, IF, WB, ELISA, and CLIA; fulfills requirements from basic research to clinical IVD development. |
Key Application Scenarios
表格
|
Suitable for Multiple Key Application Scenarios |
|
In Vitro Diagnostic (IVD) Reagent Development: Capture/detection antibody for high‑performance PSA quantitative kits (chemiluminescence, fluorescent immunochromatography) for clinical screening and monitoring. |
|
Pathological Diagnosis and Grading: Specific IHC labeling of PSA in prostate tissue sections to aid diagnosis, grading, and differential diagnosis. |
|
Liquid Biopsy and MRD Monitoring: High‑sensitivity detection of PSA on CTCs or exosomes for prognosis and recurrence surveillance. |
|
Basic and Translational Research: Investigation of PSA roles in carcinogenesis, progression, metastasis, and drug resistance. |
|
Therapeutic Antibody and ADC Development: Ideal candidate for targeted therapeutic antibodies and antibody‑drug conjugates. |
Brand Mission
ANT BIO PTE. LTD. is a premier provider of life science reagents, focusing on antibodies, proteins, assay kits, and general laboratory reagents. We operate three specialized sub‑brands: Absin (general reagents & kits), Starter (antibodies), and UA (recombinant proteins), delivering end‑to‑end solutions for basic research, translational medicine, and IVD development.
We are dedicated to supplying high‑quality, consistent, and innovative raw materials to improve the accuracy, sensitivity, and stability of clinical diagnostics and scientific research, and to drive advances in precision medicine and early cancer detection.
Related Product List
表格
|
Product Name |
Specification |
Application |
|
PSA Recombinant Rabbit Monoclonal Antibody (SDT‑195‑14) |
Customizable |
IHC, IF, WB, ELISA, CLIA, IVD kit development |
|
PSA Antibody Pair |
Matched formulation |
Quantitative immunoassay development |
|
Free PSA / Total PSA Calibrators & Controls |
Ready‑to‑use |
Diagnostic kit validation |
Brand Promotion Copy
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
